Peter O'Donnell

With a month left to join one of the 24 ERNs, Peter O'Donnell writes that this initiative is a welcomed demonstration of how cooperation can function in the common interest.

A statement from Europe's drug industry and medical societies calls for adequate funding for translational research, explaining the importance, and highlighting the challenges it faces.

Ingrid Klingmann, chair of EFGCP, speaks to Applied Clinical Trials about the efforts industry can make to change the way all stakeholders can improve clinical research.

The British government and the country's squabbling parliament are still incapable of deciding when-or even if-the UK should leave the European Union, still less how.

Right at the start of the year, the calls for radical change in the way that drug development is organized are emerging thick and fast in Europe.

The instructions of a legendary 19th recipe for jugged hare began: "First catch your hare".

As the risks grow of a disorderly UK withdrawal from the European Union, the warnings about what could go wrong for the supply of medicines in Europe become ever louder.

The decision of the leaders of the European Union over the weekend to endorse the Withdrawal Agreement for the UK's departure was historic in that it was the first time ever that the European Council had to face the imminent reality of a member state dropping out.

A high-level working group of European regulators is trying to pull together a more coherent approach to real-world evidence-and is running into difficulties with the wide range of initiatives currently underway.

October has offered a striking spectacle of contrasts in Europe's ponderous attempts to construct a comprehensive policy on health.

The mutual recognition agreement between the European Union and the US FDA now covers 15 European countries, after Portugal won US recognition in mid-September.

The workings of the European Union are notoriously complicated, with the result that misunderstanding is commonplace, even among those who might like to know more about it.

The relationship between European patients and drug developers has gone through many twists and turns over the years-and is still seeking equilibrium.

With looming workforce loss-now much higher than first anticipated-prompting further cutback plans at EMA, the threat to drug developers, suppliers, and patients is intensifying.

July has seen one very positive development in the faltering attempts by Europe's governments to resolve that challenge of providing patients with innovative medicines without bankrupting health budgets.

The British government has at last set out its ambitions for cooperation on medicines post-Brexit.

The late-June announcement that Ireland is joining the Beneluxa Initiative on Pharmaceutical Policy might suggest renewed vigour for the drive to equip national governments with more clout in their pricing negotiations with international drug firms.

How much does the EU really care about health, and about the infrastructure that is a precondition to successful healthcare and healthcare innovation?

The right-to-try gale is now blowing at full strength in the US and is likely to prove a straw in the wind that could become a haystack.

Artificial intelligence is a "new weapon" in healthcare research.

On Europe Day, the agency itself is right now keener than ever to assess its worth and the value of its services to Europe and to Europeans.

The British government continues to offer guarantees and reassurances about the post-Brexit future of its life-sciences sector despite the obvious failure so far to get even close to negotiating a withdrawal agreement with the EU.

Relocating the European Medicines Agency was always going to be hard-but no-one ever expected it to degenerate into farce.

Renewed attempts in the United States to win legislative approval for the right-to-try concept have again focused attention on that inevitably grey area between hoping a new medicine is going to be effective and demonstrating that it can be.

Relocating the European Medicines Agency was always going to be hard-but no-one ever expected it to degenerate into farce.

Peter O’Donnell weighs the varying views in Europe on the risks of going the adaptive pathways route for drug approval.

The rare disease community in Europe has come out fighting to defend its record-and its future-in the face of what it sees as growing threats to research.

Peter O’Donnell looks at efforts in Europe to improve R&D communication and trust with investors and the public.

The race to build the new EMA location in time for its move is becoming a crucial topic.

As the EMA celebrates its 2017 highlights, the new year brings deeper challenges for the agency-including preserving the credibility of its patient-first mission.